SEARCH RESULTS FOR:

David Cory

CEO, EIGER BIOPHARMACEUTICALS
United States Biopharmaceuticals 2018
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

Barbara Weber

CEO, TANGO THERAPEUTICS
United States Biopharmaceuticals 2018
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.

Ángel Tobar

GENERAL MANAGER ANDEAN REGION, EPIROC
Peru Mining 2018 Pre-Release
"Battery-charging technologies should be used in a similar way to cellphones, regardless of the brand"

Eduardo Denyer Angel

PRESIDENT, BRENNTAG LATIN AMERICA NORTH
Brenntag is growing rapidly in Mexico through aquistions and increasing market share and penetration.

Michael Bigham & Evan Loh

PARATEK PHARMACEUTICALS
United States Biopharmaceuticals 2018
Paratek focuses on drugs that target infectious disease and other difficult-to-treat conditions.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

MACIG 2025 - Mining in Africa Country Investment Guide

It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.

PARTNER EVENTS